[go: up one dir, main page]

PT2034844T - Método para o tratamento de síndrome do intestino irritável com predominância de diarreia - Google Patents

Método para o tratamento de síndrome do intestino irritável com predominância de diarreia

Info

Publication number
PT2034844T
PT2034844T PT77615417T PT07761541T PT2034844T PT 2034844 T PT2034844 T PT 2034844T PT 77615417 T PT77615417 T PT 77615417T PT 07761541 T PT07761541 T PT 07761541T PT 2034844 T PT2034844 T PT 2034844T
Authority
PT
Portugal
Prior art keywords
treatment
intestinal syndrome
irritable
diarrhea predominance
predominance
Prior art date
Application number
PT77615417T
Other languages
English (en)
Inventor
Quart Barry
Rosenbaum David
Neenan Thomas
Blanks Robert
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38648619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2034844(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of PT2034844T publication Critical patent/PT2034844T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT77615417T 2006-05-01 2007-04-30 Método para o tratamento de síndrome do intestino irritável com predominância de diarreia PT2034844T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79707406P 2006-05-01 2006-05-01
US11/510,152 US20070254050A1 (en) 2006-05-01 2006-08-24 Method for treatment of diarrhea-predominant irritable bowel syndrome

Publications (1)

Publication Number Publication Date
PT2034844T true PT2034844T (pt) 2017-06-26

Family

ID=38648619

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77615417T PT2034844T (pt) 2006-05-01 2007-04-30 Método para o tratamento de síndrome do intestino irritável com predominância de diarreia

Country Status (18)

Country Link
US (3) US20070254050A1 (pt)
EP (1) EP2034844B1 (pt)
JP (2) JP5384329B2 (pt)
KR (2) KR101487919B1 (pt)
AR (1) AR060829A1 (pt)
AU (1) AU2007248172B2 (pt)
CA (1) CA2650294C (pt)
DK (1) DK2034844T3 (pt)
ES (1) ES2628290T3 (pt)
MX (2) MX2008013871A (pt)
NZ (2) NZ595749A (pt)
PE (1) PE20081569A1 (pt)
PL (1) PL2034844T3 (pt)
PT (1) PT2034844T (pt)
SG (1) SG174025A1 (pt)
TR (1) TR201708043T4 (pt)
TW (2) TWI481410B (pt)
WO (1) WO2007130882A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
SG161259A1 (en) 2006-05-01 2010-05-27 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
EP2529626B1 (en) * 2006-05-01 2017-11-22 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
EP2719380A3 (en) * 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
WO2011044167A1 (en) * 2009-10-06 2011-04-14 University Of California, San Francisco Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
SG181810A1 (en) * 2009-12-17 2012-07-30 Univ Singapore Method of preparing derivatives/oligomers of epicatechin and applications thereof
PE20140036A1 (es) * 2010-10-31 2014-01-31 Napo Pharmaceuticals Inc Metodos y composiciones para tratar diarrea asociada con vih
WO2012135702A1 (en) 2011-04-01 2012-10-04 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
WO2012149349A2 (en) * 2011-04-27 2012-11-01 Northshore University Healthsystem Prophylaxis and treatment of enteropathogenic bacterial infection
CA2870252A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
BR112015011699B1 (pt) 2012-11-21 2021-01-12 KBS Research, LLC suplementos herbais e respectivos usos
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
CN104873485B (zh) * 2015-05-08 2019-02-19 中国药科大学 槲皮素治疗与胃肠道应激失调相关疾病的用途
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
IT201600122310A1 (it) * 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
ES2953520T3 (es) 2016-12-23 2023-11-14 Maregade Rx Llc Producto a baja dosis y método para el tratamiento de la diarrea
MX394171B (es) * 2017-03-06 2025-03-24 Athena Pharmaceutiques Sas Una composicion farmaceutica que comprende racecadotrilo y procedimiento para preparar la misma
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
CA3139930A1 (en) * 2019-06-12 2020-12-17 Alan S. Verkman Methods of treating bile acid diarrhea
CN113975412B (zh) * 2021-12-30 2022-04-05 北京赛尔富森生物科技有限公司 一种评价轮状病毒疫苗有效性的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
FI962667L (fi) 1996-06-27 1997-12-28 Scanwoven Ab Oy Kuitutuote, menetelmä ja laitteisto kuitutuotteen valmistamiseksi
EP0935417B1 (en) 1996-10-16 2009-05-06 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US7208183B2 (en) * 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
EP2529626B1 (en) 2006-05-01 2017-11-22 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing colon cancer
SG161259A1 (en) 2006-05-01 2010-05-27 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011044167A1 (en) 2009-10-06 2011-04-14 University Of California, San Francisco Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
PE20140036A1 (es) 2010-10-31 2014-01-31 Napo Pharmaceuticals Inc Metodos y composiciones para tratar diarrea asociada con vih
MX2015007065A (es) 2012-12-07 2017-03-01 Napo Pharmaceuticals Inc Metodo y composiciones para tratar diarrea asociada con vih.

Also Published As

Publication number Publication date
JP2009535417A (ja) 2009-10-01
JP5384329B2 (ja) 2014-01-08
JP5820440B2 (ja) 2015-11-24
KR101537361B1 (ko) 2015-07-17
AR060829A1 (es) 2008-07-16
KR20090009291A (ko) 2009-01-22
PL2034844T3 (pl) 2017-09-29
JP2014012695A (ja) 2014-01-23
TW200810772A (en) 2008-03-01
AU2007248172B2 (en) 2013-03-21
EP2034844A4 (en) 2010-11-17
CA2650294C (en) 2019-01-22
KR101487919B1 (ko) 2015-02-03
AU2007248172A1 (en) 2007-11-15
TWI574694B (zh) 2017-03-21
TR201708043T4 (tr) 2018-11-21
NZ609344A (en) 2014-08-29
US20150050338A1 (en) 2015-02-19
NZ595749A (en) 2013-11-29
KR20130063552A (ko) 2013-06-14
PE20081569A1 (es) 2009-01-14
US8846113B2 (en) 2014-09-30
ES2628290T3 (es) 2017-08-02
WO2007130882A3 (en) 2008-02-07
EP2034844A2 (en) 2009-03-18
CA2650294A1 (en) 2007-11-15
MX382400B (es) 2025-03-13
US20070254050A1 (en) 2007-11-01
SG174025A1 (en) 2011-09-29
WO2007130882A2 (en) 2007-11-15
TW201434475A (zh) 2014-09-16
DK2034844T3 (en) 2017-06-06
TWI481410B (zh) 2015-04-21
US20120189720A1 (en) 2012-07-26
EP2034844B1 (en) 2017-03-22
MX2008013871A (es) 2009-01-07
US9980938B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
PT2034844T (pt) Método para o tratamento de síndrome do intestino irritável com predominância de diarreia
PT2241318E (pt) Método para tratamento da síndrome do cólon irritável, com predominância de obstipação
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
PL2190883T3 (pl) Sposób obróbki biomasy
EP4125244C0 (en) HASH BASED MULTIHOSTING
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
FI20060288A0 (fi) Pinnoitusmenetelmä
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0809651A2 (pt) Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada
DE602007013995D1 (de) Beschichtungsverfahren
BRPI0813569A2 (pt) Método de inspeção.
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0911580A2 (pt) composições para o tratamento de uma condição artrítica
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
EP1971589A4 (en) PROCESS FOR PREPARING 3-HYDROXYTETRAHYDROFURAN BY MEANS OF CYCLODE HYDROGENATION
LU93092I2 (de) Alemtuzumab
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
EP1981964A4 (en) MYCOBACTERIAL SECA2 MUTANTS
FI20065434L (fi) Menetelmä kampiakselin käsittelemiseksi
BRPI0820954A2 (pt) Processo de combustão
EP1946857A4 (en) PROCESS FOR MODIFYING ASBESTOS
BRPI0815055A2 (pt) aparelho de ciclone.
BRPI0715087A2 (pt) Método de tratamento de disfunção termoregulatória com paroxetina